Share Email Print
cover

Journal of Biomedical Optics

D-galactose receptor-targeted in vivo spectral fluorescence imaging of peritoneal metastasis using galactosamin-conjugated serum albumin-rhodamine green
Format Member Price Non-Member Price
PDF $20.00 $25.00

Paper Abstract

The wavelength resolved spectral fluorescence imaging technique using a fluorescein-conjugated avidin has been reported to visualize submillimeter implants of ovarian cancer because of its highly targeted and quickly cleared pharmacokinetics. However, clinical application of avidin was hampered by its strong immunogenicity. As a clinically feasible alternative to avidin, which targets the same D-galactose receptor but is made from a nonimmunogenic source, with even better binding capability by multiplying binding sites but still maintaining a favorable characteristic of high isoelectric point, a serum albumin conjugated with 23 galactosamine and 2 rhodamine green molecules (GmSA-RhodG) was designed and synthesized. GmSA-RhodG showed more than 10-fold rapid and higher uptake by SHIN3 ovarian cancer cells than both avidin- and no galactosamine-conjugated albumin (bovine serum)–RhodG. Sensitivity and specificity of GmSA-RhodG to detect red fluorescence labeled peritoneal cancer foci in mouse cancer model were 100%/99% (n=566), respectively for 1-~mm lesions and even smaller lesions were detected in vivo. These results indicate that GmSA-RhodG is not only a clinically feasible alternative but more efficient targeting reagent for D-galactose receptors than avidin-RhodG.

Paper Details

Date Published: 1 September 2007
PDF: 9 pages
J. Biomed. Opt. 12(5) 051501 doi: 10.1117/1.2779351
Published in: Journal of Biomedical Optics Volume 12, Issue 5
Show Author Affiliations
Yukihiro Hama, National Institutes of Health (United States)
Yasuteru Urano, The Univ. of Tokyo (Japan)
Yoshinori Koyama, National Institutes of Health (United States)
Peter L. Choyke, National Institutes of Health (United States)
Hisataka Kobayashi, National Institutes of Health (United States)


© SPIE. Terms of Use
Back to Top